There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cidara Therapeutics (CDTX), Pluristem (PSTI) and Tesaro (TSRO) with bullish sentiments.
Cidara Therapeutics (CDTX)
Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Cidara Therapeutics today and set a price target of $15. The company’s shares opened today at $3.57, close to its 52-week low of $3.05.
Chen wrote:
“CDTX’s pipeline is focused on better ways to treat fungal and bacterial infections as well as influenza. We expect pipeline advancements to drive upwards earnings revisions to levels not yet reflected in the consensus. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $15.”
According to TipRanks.com, Chen is a 4-star analyst with an average return of 10.2% and a 39.5% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Amneal Pharmaceuticals Inc.
Cidara Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $15.
See today’s analyst top recommended stocks >>
Pluristem (PSTI)
Maxim Group analyst Jason McCarthy maintained a Buy rating on Pluristem today and set a price target of $3. The company’s shares opened today at $1.10, close to its 52-week low of $1.03.
McCarthy wrote:
“Pluristem presented data from its ongoing Phase 1 study of PLX-R18 treatment for patients with incomplete hematopoietic recovery after hematopoietic stem cell transplantation (HCT) at ASH.”
According to TipRanks.com, McCarthy is a 2-star analyst with an average return of 0.3% and a 37.7% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pluristem with a $3.25 average price target.
Tesaro (TSRO)
In a report released today, Alethia Young from Cantor Fitzgerald maintained a Buy rating on Tesaro, with a price target of $68. The company’s shares opened today at $73.68.
Young noted:
“: This morning, Tesaro (TSRO) announced that it has entered into a definitive agreement to be acquired by GlaxoSmithKline (GSK) for $75/share in cash or a total enterprise value of $5.1B, representing a 62% premium over TSRO closing price as of last Friday (11/30). The deal is consistent with our recent M&A analysis (NOTE), and comes in slightly under our estimated potential acquisition enterprise value of $5.6B. An acquisition was widely expected after Bloomberg recently reported that Tesaro was exploring a sale. We view this news to be positive for TSRO shareholders, who have been very focused on Tesaro’s funding needs given the current quarterly burn rate of $137M.”
According to TipRanks.com, Young is a 4-star analyst with an average return of 4.7% and a 48.2% success rate. Young covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Puma Biotechnology, and Intercept Pharma.
Currently, the analyst consensus on Tesaro is a Moderate Buy with an average price target of $53.36, a -27.6% downside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $69 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
